Fibroblast growth factor receptor (FGFR) mutations and fusions are relevant biomarkers in metastatic urothelial carcinoma (mUC). However, the prevalence of genomic alterations and their impact on clinical outcomes in a Latin American population remains unknown. This study aimed to explore the prevalence of FGFR mutations and/or fusions in patients with mUC in Latin America (LATAM) and its association with clinicopathological characteristics, Bellmunt's prognostic model, and survival outcomes.
A multicenter retrospective cohort study from 2016 to 2019 of patients with mUC from several LACOG LATAM institutions. FGFR alterations were analyzed by real-time PCR and/or next-generation sequencing in tumor samples and clinicopathologic characteristics and survival outcomes data were collected. The prevalence of FGFR, patient characteristics, and treatment in real-world settings were summarized. Kaplan-Meier survival estimates and Cox regression analyses were used to evaluate the associations of FGFR mutation and/or fusion status with median overall survival (mOS), median time to treatment failure (mTTF), and clinicopathological characteristics.
In total, 222 patients were screened. Of these, 196 patients were considered eligible and were included in the analysis. FGFR mutations and/or fusions were found in 35 (17.9%) patients. There was no statistical difference in mOS and mTTF in FGFR-altered and non-altered patients (13.1 vs. 16.8 months, P = .20 and 3.9 vs. 4.1 months, P = .96, respectively). Bellmunt's prognostic model correctly predicted overall survival (P = .049).
This is the largest study evaluating the prevalence of FGFR alterations in patients with mUC in the LATAM population. FGFR alterations in mUC were found in 17.9% of the patients, and the presence of this biomarker was not associated with OS. We validated Bellmunt's prognostic model in this cohort.
Clinical genitourinary cancer. 2024 Jul 25 [Epub ahead of print]
Vinicius Carrera Souza, Fernando Sabino Marques Monteiro, Fernando Cotait Maluf, Gustavo Werutsky, Vanessa de Carvalho Fabrício, Rosemarie Gidekel, Maria Natalia Gandur-Quiroga, Marcelo Roberto Pereira Freitas, Murilo Luz, Saul Campos-Gomez, Jose Augusto Rinck Junior, Diogo Assed Bastos, Juan Pablo Sade, Karine Martins da Trindade, Augusto Cesar de Andrade Mota, Roni de Carvalho Fernandes, Allan Omar Barillas Ruíz, Breno Dauster Pereira E Silva, Fernando Nunes Galvão de Oliveira, Hernan Javier Cutuli, Lucas Nogueira, Luis Fernando García Aceituno, Mauricio Fernandez, Eva Inman, Manuel Caitano, Daniel Herchenhorn, Jaime Ardila-Salcedo, Patrícia Pacheco, Rafaela Gomes de Jesus, Gustavo Gössling, Andrey Soares, André Poisl Fay
Oncologia D' Or Salvador, Salvador, Brazil. Electronic address: ., Hospital Universitário de Brasília (UNB), Brasília, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Beneficência Portuguesa de São Paulo, São Paulo, Brazil., Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Janssen Latin America, Buenos Aires, Argentina., Instituto de Oncologia Ángel H. Roffo, Buenos Aires, Argentina., Centro de Pesquisas Oncológicas (CEPON), Florianópolis, Brazil., 5Hospital Erasto Gaertner, Curitiba, Brazil., Centro Oncológico Estatal ISSEMYM, Toluca de Lerdo, Mexico., A.C. Camargo, São Paulo, Brazil., Hospital Sírio-Libanês, São Paulo, Brazil., Instituto Alexander Fleming, Buenos Aires, Argentina., IEP Oncocentro, Fortaleza, Brazil., Clínica AMO - Assistência Multidisciplinar em Oncologia, Salvador, Brazil., Santa Casa de São Paulo, São Paulo, Brazil., Clínicas Médicas Especializadas NUCARE, Ciudad de Guatemala, Guatemala., Hospital São Rafael, São Paulo, Brazil., CLION, Salvador, Brazil., Asociacion de Beneficencia Hospital Sirio-Libanes, Buenos Aires, Argentina., Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil., Clinica Oncologica, Ciudad de Guatemala, Guatemala., COIR - Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina., ONCOR, Saltillo Coahuila, Mexico., Centro de Oncologia do Paraná, Curitiba, Brazil., Oncologia D'OR/Instituto D'OR de Ensino e Pesquisa, Rio De Janeiro, Brazil., Janssen Latin America, Bogota, Colombia., Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Centro Paulista de Oncologia (CPO) - Grupo Oncoclinicas, São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil., Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Centro de Pesquisa em Oncologia (CPO) - Hospital São Lucas da PUCRS, Porto Alegre, Brazil.